Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

121 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Chemotherapy versus tamoxifen versus chemotherapy plus tamoxifen in node-positive, oestrogen-receptor positive breast cancer patients. An update at 7 years of the 1st GROCTA (Breast Cancer Adjuvant Chemo-Hormone Therapy Cooperative Group) trial.
Boccardo F, Rubagotti A, Amoroso D, Sismondi P, Genta F, Nenci I, Piffanelli A, Farris A, Castagnetta L, Traina A, et al. Boccardo F, et al. Among authors: rubagotti a. Eur J Cancer. 1992;28(2-3):673-80. doi: 10.1016/s0959-8049(05)80123-6. Eur J Cancer. 1992. PMID: 1591091 Clinical Trial.
Chemotherapy versus tamoxifen versus chemotherapy plus tamoxifen in node-positive, estrogen receptor-positive breast cancer patients: results of a multicentric Italian study. Breast Cancer Adjuvant Chemo-Hormone Therapy Cooperative Group.
Boccardo F, Rubagotti A, Bruzzi P, Cappellini M, Isola G, Nenci I, Piffanelli A, Scanni A, Sismondi P, Santi L, et al. Boccardo F, et al. Among authors: rubagotti a. J Clin Oncol. 1990 Aug;8(8):1310-20. doi: 10.1200/JCO.1990.8.8.1310. J Clin Oncol. 1990. PMID: 2199618 Clinical Trial.
Ovarian ablation versus goserelin with or without tamoxifen in pre-perimenopausal patients with advanced breast cancer: results of a multicentric Italian study.
Boccardo F, Rubagotti A, Perrotta A, Amoroso D, Balestrero M, De Matteis A, Zola P, Sismondi P, Francini G, Petrioli R, et al. Boccardo F, et al. Among authors: rubagotti a. Ann Oncol. 1994 Apr;5(4):337-42. doi: 10.1093/oxfordjournals.annonc.a058837. Ann Oncol. 1994. PMID: 8075030 Free article. Clinical Trial.
Endocrine therapy of breast cancer. The experience of the Italian Cooperative Group for Chemohormonal Therapy of Early Breast Cancer (GROCTA).
Boccardo F, Amoroso D, Rubagotti A, Sismondi P, De Sanctis C, Cappellini M, Pacini P, Castagnetta L, Traina A, Farris A, et al. Boccardo F, et al. Among authors: rubagotti a. Ann N Y Acad Sci. 1993 Nov 30;698:318-29. doi: 10.1111/j.1749-6632.1993.tb17222.x. Ann N Y Acad Sci. 1993. PMID: 8279771 Clinical Trial. No abstract available.
Lack of effectiveness of adjuvant alternating chemotherapy in node-positive, estrogen-receptor-negative premenopausal breast cancer patients: results of a multicentric Italian study. The Breast Cancer Adjuvant Chemo-Hormone Therapy Cooperative Group (GROCTA).
Boccardo F, Rubagotti A, Amoroso D, Perrotta A, Sismondi P, Farris A, Mesiti M, Gallo L, Pacini P, Villa E, Agostara B. Boccardo F, et al. Among authors: rubagotti a. Cancer Invest. 1997;15(6):505-12. doi: 10.3109/07357909709047591. Cancer Invest. 1997. PMID: 9412655 Clinical Trial.
Italian Breast Cancer Adjuvant Chemo-Hormone Therapy Cooperative Group Trials. GROCTA Trials.
Boccardo F, Rubagotti A, Amoroso D, Mesiti M, Pacini P, Gallo L, Sismondi P, Giai M, Genta F, Mustacchi G, Agostara B, Bolognesi A, Villa E, Schieppati G, Ausili Cefaro GP, Bellantone R, Farris A, Sassi M, Patrone F. Boccardo F, et al. Among authors: rubagotti a. Recent Results Cancer Res. 1998;152:453-70. doi: 10.1007/978-3-642-45769-2_44. Recent Results Cancer Res. 1998. PMID: 9928580 Review.
Cyclophosphamide, methotrexate, and fluorouracil versus tamoxifen plus ovarian suppression as adjuvant treatment of estrogen receptor-positive pre-/perimenopausal breast cancer patients: results of the Italian Breast Cancer Adjuvant Study Group 02 randomized trial. boccardo@hp380.ist.unige.it.
Boccardo F, Rubagotti A, Amoroso D, Mesiti M, Romeo D, Sismondi P, Giai M, Genta F, Pacini P, Distante V, Bolognesi A, Aldrighetti D, Farris A. Boccardo F, et al. Among authors: rubagotti a. J Clin Oncol. 2000 Jul;18(14):2718-27. doi: 10.1200/JCO.2000.18.14.2718. J Clin Oncol. 2000. PMID: 10894871 Clinical Trial.
Chemotherapy versus tamoxifen versus chemotherapy plus tamoxifen in node-positive, oestrogen receptor-positive breast cancer patients. Very late results of the 'gruppo di ricerca per la chemio-ormonoterapia adiuvante (GROCTA)' 01-Trial in early breast cancer.
Boccardo F, Guglielmini P, Parodi A, Rubagotti A. Boccardo F, et al. Among authors: rubagotti a. Breast Cancer Res Treat. 2011 Apr;126(3):653-61. doi: 10.1007/s10549-011-1405-6. Epub 2011 Feb 24. Breast Cancer Res Treat. 2011. PMID: 21347647 Clinical Trial.
Zoladex with or without flutamide in the treatment of locally advanced or metastatic prostate cancer: interim analysis of an ongoing PONCAP study. Italian Prostatic Cancer Project (PONCAP).
Boccardo F, Decensi A, Guarneri D, Rubagotti A, Oneto F, Martorana G, Giuliani L, Delli Ponti U, Petracco S, Cortellini P, et al. Boccardo F, et al. Among authors: rubagotti a. Eur Urol. 1990;18 Suppl 3:48-53. doi: 10.1159/000463981. Eur Urol. 1990. PMID: 2151277 Clinical Trial.
121 results